BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, April 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 5, 2003
View Archived Issues
European Institutes Stepping In To Add Value To Technologies
Read More
To-Do List For European Biotech: Harmonize, Get Drugs, Go Global
Read More
Correction
Read More
AVI Adds $15M To Balance Sheet Through Direct Equity Placement
Read More
Genzyme Prices Placement Of $600M In Convertible Notes
Read More
Other News To Note
Read More
Merck, Actelion Enter Potential $272M Deal On Renin Inhibition
In its second deal of the week, Merck & Co. Inc. tapped Swiss firm Actelion Inc. for a potential $272 million agreement to develop new classes of renin inhibitors for cardio-renal diseases. (BioWorld Today)
Read More
KAI Completes $17M Series A For Work In Protein Kinase C
Read More